Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Body mass index (BMI) may not provide the most accurate screening for skeletal muscle deficits among youth with pediatric‐onset inflammatory bowel disease (IBD), according to a study in the Journal of ...

Treatment with RBL was effective against recurrent CDI among high-risk patients when administered at home or in clinical settings.

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

The US FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.

While CVS hospitalizations have declined, the illness continues to present among young women, Black individuals, and leads to high costs among Hispanic patients.

Subcutaneous infliximab therapy alone is associated with higher immunogenicity than IV infliximab and an immunomodulator combined.

Janus kinase (JAK) inhibitors are not associated with an increased risk for gastrointestinal perforation (GIP) among patients with rheumatoid arthritis (RA), according to study results published in ...